Emerg­ing from he­pati­tis B flops, As­sem­bly Bio show­cas­es ear­ly da­ta on next-gen drugs

3 years ago
R&D

Pfiz­er opts in to net Lian­Bio’s rights to RSV can­di­date, putting down $20M up­front

3 years ago
Deals
R&D

FDA lifts hold on stud­ies of blue­bird's sick­le cell gene ther­a­py in ado­les­cents

3 years ago
R&D
Cell/Gene Tx

Madri­gal’s NASH drug wins on piv­otal PhI­II end­points, set­ting stage for ac­cel­er­at­ed ap­proval

3 years ago
R&D

Sanofi plucks three more NK cell en­gagers from French biotech part­ner, putting down €25M cash

3 years ago
Deals
Cell/Gene Tx

Alzheimer's fail crush­es small biotech's share price to near­ly pen­ny stock

3 years ago
R&D

As­traZeneca's Imfinzi fails in lung can­cer tri­al as a monother­a­py to im­prove OS

3 years ago
R&D

Scoop: A2 Bio­ther­a­peu­tics rais­es $62M for sol­id tu­mor cell ther­a­pies

3 years ago
Financing
Startups

Am­gen to buy Hori­zon for $28B; Mer­ck, Mod­er­na tout can­cer vac­cine; FDA ap­proves sec­ond KRAS drug; and more

3 years ago
Weekly

Q&A: Ire­land bio­phar­ma leader dis­cuss­es the na­tion’s 2022 boost in man­u­fac­tur­ing

3 years ago
Pharma
Manufacturing

Black­stone re­con­sid­ers fu­ture of Japan­ese phar­ma — re­port

3 years ago
Deals
Pharma

FDA ap­proves Fer­ring's new gene ther­a­py for blad­der can­cer

3 years ago
Cell/Gene Tx
FDA+

FDA sched­ules Covid-19 vac­cine ad­comm to dis­cuss po­ten­tial mod­i­fi­ca­tions and boost­ers

3 years ago
FDA+

Biden signs stop­gap fund­ing through next week as ne­go­tia­tors prep for larg­er om­nibus bill

3 years ago
FDA+
Law

US-list­ed Chi­nese biotechs dodge threat of delist­ing

3 years ago
Pharma

What FDA might con­sid­er as de­lay­ing or deny­ing an in­spec­tion: New guid­ance spells out the specifics

3 years ago
FDA+
Manufacturing

As­traZeneca nabs 6 more months for Sym­bi­cort patent in lat­est court rul­ing

3 years ago
Pharma
Law

EMA rec­om­mends he­mo­phil­ia B gene ther­a­py for ap­proval, de­nies Y-mAbs neu­rob­las­toma drug

3 years ago
Cell/Gene Tx

#ASH22 Re­cap: Lead­ing hema­tol­ogy ex­perts talk top read­outs; Fire­side chat with No­vo Nordisk's Lu­dovic Helf­gott; More

3 years ago
R&D
Discovery

Dr. Red­dy's sub­sidiary hits the pause but­ton on drug de­vel­op­ment for pso­ri­a­sis

3 years ago
R&D

Al­ny­lam's R&D up­date in­cludes 3 halts, Alzheimer's time­line and an­oth­er NASH

3 years ago
R&D

SPAC ex­tends dead­line to merge — again; Flag­ship's Evelo bor­rows $45M to re­fi­nance debt

3 years ago
News Briefing

Scoop: As Sio clos­es, for­mer CEO from ‘vant ex­it finds him­self at helm of Irv Weiss­man stealth biotech

3 years ago
Startups
R&D

Scoop: Mod­er­na co-founder's re­gen­er­a­tive med­i­cine biotech nabs funds, but los­es Genen­tech

3 years ago
Financing
Startups
First page Previous page 412413414415416417418 Next page Last page
A service from the Financial Times